Shilpa unit, Steincares to commercialize a biosimilar in Latam

Shilpa unit, Steincares to commercialize a biosimilar in Latam

SteinCares and Bio-Thera Solutions Expand Biosimilar Collaboration in Latin America

SteinCares, a leading specialty healthcare company in Latin America, and Bio-Thera Solutions, a China-based biopharmaceutical firm, have announced a partnership to commercialize a biosimilar of dupilumab across Latin America. This agreement marks the fourth collaboration between the two companies and aims to provide a cost-effective alternative to a top-selling biologic, enhancing access to treatments for chronic inflammatory diseases.

Under the terms of the agreement, Bio-Thera Solutions will oversee product development and supply, while SteinCares will manage regulatory registration and commercialization in the region according to the partnership terms. The partnership aligns with SteinCares' strategy to strengthen its position as a key biosimilar provider in Latin America, leveraging its established commercial network to deliver affordable therapies.

Dupilumab, a biologic used to treat conditions such as atopic dermatitis and asthma, ranks among the world's top five medicines by annual sales value. A biosimilar alternative could reduce treatment costs for patients and healthcare systems, particularly in markets where specialty drug expenditures are rising. The collaboration also reflects growing demand for biosimilars in Latin America, where regulatory frameworks are increasingly supportive of market access for these products.

Bio-Thera Solutions, which has previously secured approvals for biosimilars like adalimumab and bevacizumab in China and the U.S., brings technical expertise to the partnership. SteinCares, with operations in over 30 Latin American countries, has a track record of introducing innovative therapies to the region. The companies emphasized that the dupilumab biosimilar will undergo rigorous development to ensure safety and efficacy comparable to the reference product.

The partnership underscores the potential for cross-regional collaborations in the biosimilars sector, as manufacturers seek to address unmet medical needs while controlling healthcare costs. Investors may monitor regulatory progress and market adoption, as successful commercialization could expand SteinCares' revenue streams and Bio-Thera's global footprint.

(https://steincares.com/bio-thera-steincares-dupilumab-biosimilar-latin-america/): https://steincares.com/bio-thera-steincares-dupilumab-biosimilar-latin-america/